Name: Deflazacort
Brand: Selleck Chemicals
SKU: S1888
Availability: InStock
Rating: 5 (1 reviews)

Jump to

Quality Control

Batch: S188801 DMSO]88 mg/mL]false]Ethanol]12 mg/mL]false]Water]Insoluble]false Purity: 99.91%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS
Datasheet

99.91

Related Targets	Adrenergic Receptor Estrogen/progestogen Receptor GPR Androgen Receptor ACE RAAS Progesterone Receptor Opioid Receptor PGES THR
Other Glucocorticoid Receptor Inhibitors	Corticosterone AL082D06 (20S)-Protopanaxatriol Cortodoxone

Solubility

In vitro
Batch:

DMSO : 88 mg/mL (199.31 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 12 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	441.52	Formula	C₂₅H₃₁NO₆	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	14484-47-0	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	MDL 458			Smiles	CC1=NC2(C(O1)CC3C2(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)C(=O)COC(=O)C

Mechanism of Action

Targets/IC₅₀/Ki	Glucocorticoid receptor
In vivo	Deflazacort results in a significant and equal decrease of thymus weight, indicating a marked reduction in total immunogenic tissue in rats. This compound reduces thymus weight and Daily weight gain in rats. It lowers liver IFG-I and GHR mRNA in rats. This chemical is a heterocyclic glucocorticoid with anti-inflammatory activity but with decreased side effects. It and [3H]dexamethasone (DEX) similarly induce in vivo ornithine decarboxylase activity in hippocampus and liver, although body weight loss after chronic treatment is significantly less for DFC. This compound induces dose-dependent decreases in osteocalcin (OC) plasma production rate (PPR). It and prednisolone increase both postabsorptive plasma glucose and plasma calcium levels in sheep, but there are no significant differences between their effects. This compound, especially combined with L-arginine, spares quadriceps muscle from injury-induced regeneration (myf5 expression) compared with placebo treatment, despite an increase in membrane permeability immediately after exercise. It alone prevents the typical progressive loss of function (measured as voluntary distance run over 24 hours) that is observed 3 months later in placebo-treated mice. It causes a less significant alteration in the pattern of GH secretion and does not negatively affect the overall amount of GH secreted.
References	[1] https://pubmed.ncbi.nlm.nih.gov/22192593/ [2] https://pubmed.ncbi.nlm.nih.gov/7804450/ [3] https://pubmed.ncbi.nlm.nih.gov/8003438/ [4] https://pubmed.ncbi.nlm.nih.gov/8402319/ [5] https://pubmed.ncbi.nlm.nih.gov/16464957/ [6] https://pubmed.ncbi.nlm.nih.gov/10229911/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04791345	Unknown status	Healthy Volunteers	Parc de Salut Mar	February 26 2021	Phase 1
NCT03783923	Terminated	Limb-Girdle Muscular Dystrophy	PTC Therapeutics	October 31 2019	Phase 3
NCT03642145	Withdrawn	Duchenne Muscular Dystrophy	PTC Therapeutics	October 31 2018	Phase 3
NCT02251600	Completed	Duchenne Muscular Dystrophy	PTC Therapeutics	December 2014	Phase 1
NCT02286622	Completed	Renal Impairment	PTC Therapeutics	December 2014	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Deflazacort Glucocorticoid Receptor agonist

Chemical Structure

Molecular Weight: 441.52